Euro
USD
British Pound
NULL
Product Description
Pembrolizumab (Keytruda) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Pembrolizumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells.
Biovision | A2073 | Anti-PD-1 (Pembrolizumab) Biotinylated Antibody DataSheet
Antibody Target: PD-1 (Pembrolizumab)
Target Alternative Name:
Tag Line: Affinity purified recombinant monoclonal antibody to detect biotinylation of PD-1 in human samples
Category: Primary antibody
Host: Recombinant
Isotype: Human IgG4
Species Reactivities: Human
Immunogen Sequence: Human programmed cell death 1 receptor (PD-1)
Accession #: Q02242
Gene ID: 18566
Appearance: Colorless liquid
Form: Liquid
Concentration: 0.5 mg/ml
Formulation: In PBS, 30% glycerol, 0.5% BSA, 0.5 mM EDTA and 0.03% proclin, pH 7.2
Purification: Affinity purified
Application: ELISA
Positive Control:
Application And Usages: ELISA 0.5 - 1 µg/ml
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: False
Immunocytochemistry Verified: False
Immunofluorescence Verified: False
Immunoprecipitation Verified: False
FACS Verified: False
ELISA Verified: True
ChIP Verified: False
Dot Blot Verified: False
Flow Cytometry Verified: False
